AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$GKOS

Glaukos: Q3 Earnings Snapshot

Glaukos Corp. (GKOS) reported Q3 net income of $2M, or 3 cents per share, and adjusted earnings of 47 cents per share, beating analyst expectations. Revenue was $211M, exceeding forecasts of $168.8M. The company expects full-year revenue between $775M and $785M.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 8:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Glaukos: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$GKOSBullishMed
01

Why it matters

Earnings beat may trigger buying interest and short‑covering in the near term.

02

Market read

First‑time earnings disclosure with a beat; relevant for traders focused on biotech earnings momentum.

03

What to watch

Potential headwinds from reimbursement pressures and competitive pipeline.

Relevance 7/10Novelty 8/10Timing: post‑market today

Background

Glaukos is a developer of glaucoma treatments; the earnings release provides the first public disclosure of Q3 results.

Company-level read

Ticker impact

$GKOSBullishHigh confidence
Context

Glaukos reported Q3 net income of $2 M, EPS 3 cents beating analysts' loss estimate of -12 cents and revenue $211 M beating the $168.8 M consensus.

Expected impact

likely upward as market prices in the earnings beat

Evidence & confidence

Both earnings and revenue exceeded expectations, providing a clear catalyst for short‑term buying.

Market effects

Sector

Positive earnings may lift other ophthalmology and eye‑care stocks.

Regional

Limited to US biotech/healthcare segment.

Global

Modest; primarily affects US‑listed eye‑care sector.

Counterpoint

What could challenge this read

If guidance for FY revenue falls short of expectations, the rally could be short‑lived.

Key entities

  • company
    Glaukos Corp.

    NASDAQ‑listed ophthalmology company.

Read at source← All news

StoryGlaukos reports record Q3 sales, beats expectations and lifts 2026‑2027 revenue outlook

Also covered by

5 outlets

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

finance.yahoo.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

timothysykes.com
$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

stockstotrade.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

timothysykes.com
$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.

investing.com